No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BIB Ultra Nasdaq Biotechnology Proshares
- 53.740
- +1.160+2.21%
Close May 2 16:00 ET
54.160High52.357Low
54.160High52.357Low17.50KVolume53.310Open52.580Pre Close934.23KTurnover1.09%Turnover Ratio--P/E (Static)1.60MShares62.40552wk High--P/B85.98MFloat Cap40.04352wk Low0.08Dividend TTM1.60MShs Float112.860Historical High0.15%Div YieldTTM3.43%Amplitude4.233Historical Low53.400Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Why Moderna Stock Blasted 13% Higher Today
Amgen Inc (AMGN) Q1 2024 Earnings: Aligns With EPS Projections Amid Revenue Growth and Challenges
Amgen Stock Rallies 13% on Weight-loss Drug Updates, Tweaked Guidanace
Amgen Rallies 10%+ After Hours on Q1 Earnings and Revenue Beats, Plus Well-Received Full-Year Guidance
Amgen Rallies 10%+ After Hours on Q1 Earnings and Revenue Beats, Plus Well-Received Full-Year Guidance
Amgen, DraftKings, Live Nation: Trending Tickers
Amgen Expects Data From Weight-loss Drug Trial Later This Year
By Claudia Assis Shares of Amgen rally 11% after Q1 earnings Shares of Amgen Inc. rallied more than 11% in the extended session Thursday after the drugmaker posted adjusted earnings above expectatio
Comments
Do you have a bullish outlook on the biotech sector for 2024? Feel free to share and discuss in the comments below.🥰 $SPDR S&P Biotech ETF(XBI.US$$Ultra Nasdaq Biotechnology Proshares(BIB.US$$iShares Biotechnology ETF(IBB.US$
5
1
Health Care Sector Update for 08/24/2022: SPRC,GKOS,BCDA
$Ultra Nasdaq Biotechnology Proshares(BIB.US$ was climbing 1.5%.
$SciSparc(SPRC.US$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos(GKOS.US$ gained 6% after We...
$SciSparc(SPRC.US$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos(GKOS.US$ gained 6% after We...
3
Read more